Baird Financial Group Inc. Sells 47,449 Shares of Hologic, Inc. $HOLX

Key Points

• Baird Financial Group Inc. significantly reduced its stake in Hologic, Inc. by 70.2%, selling 47,449 shares and now holds 20,169 shares valued at approximately $1,246,000.
• Hologic, Inc. reported quarterly earnings of $1.08 per share, exceeding analyst expectations, with a revenue of $1.02 billion for the quarter.
• Several analysts have upgraded Hologic's stock rating, with Royal Bank Of Canada increasing the target price from $72.00 to $87.00, reflecting a positive outlook for the company's performance.

Baird Financial Group Inc. reduced its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 70.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,169 shares of the medical equipment provider's stock after selling 47,449 shares during the period. Baird Financial Group Inc.'s holdings in Hologic were worth $1,246,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HOLX. Zions Bancorporation National Association UT acquired a new stake in Hologic in the 1st quarter worth $34,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Hologic during the first quarter valued at about $42,000. Raiffeisen Bank International AG bought a new stake in shares of Hologic in the fourth quarter valued at about $49,000. Allworth Financial LP lifted its stake in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 216 shares during the period. Finally, Larson Financial Group LLC grew its position in Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after buying an additional 722 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

HOLX opened at $66.54 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock has a market capitalization of $14.80 billion, a P/E ratio of 27.61, a price-to-earnings-growth ratio of 2.42 and a beta of 0.57. The company's 50 day simple moving average is $66.37 and its 200-day simple moving average is $62.60. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the business earned $1.06 earnings per share. The firm's quarterly revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the subject of several research reports. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and raised their target price for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Morgan Stanley increased their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Argus raised shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a report on Monday, August 18th. UBS Group lifted their target price on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.